TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03749746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Health 4 New Moms
Description: The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
Study: NCT01735721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Sinus Lift
Description: A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Sinus Lift
Description: A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material.
Study: NCT02355964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobe exercise 3 times a week in 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobe exercise 3 times a week in 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
Study: NCT02208713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Description: Intramuscular injection of stem cells in patients with FSHD.
Study: NCT04242290

Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral radiography
Description: The lordosis angles were measured on the lateral cervical graphs of all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral radiography
Description: The lordosis angles were measured on the lateral cervical graphs of all patients.
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT03215173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit After Baby
Description: Mobile application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text4Baby Control Group
Description: Receive free text messages
Study: NCT01535820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT01535820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT04202939

Intervention type: OTHER
Intervention: nutrition
Description: type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
Study: NCT03474302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Aerobic, strength training, balance, flexibility

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: Healthy aging education
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT02725944

Intervention type: DEVICE
Intervention: Implantation of ICRM
Description: All patients will be implanted with ICRM in order to detect an occult PAF.
Study: NCT01797120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
Study: NCT01919294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone undecanoate
Description: Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
Study: NCT01014390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex Biliary RX Fully Covered Stent System
Description: Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
Study: NCT03908021

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome analysis and 16S rRNA gene-based analysis
Description: microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03765268

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurectomy in inguinal hernia repair
Description: Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve sparing in inguinal hernia repair
Description: Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
Study: NCT04170179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
Study: NCT02024607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study: NCT01644708

Intervention type: BEHAVIORAL
Intervention: Self empowerment
Description: 1. Group meeting, introducing the method and the assessment tools~1. Self-empowerment,~2. Handing over the journal,~3. Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal.
Study: NCT00205556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: on-line hemodiafiltration
Description: addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: low flux hemodialysis
Description: standard treatment
Study: NCT02610374

Intervention type: OTHER
Group type: OTHER
Intervention: Agrarian Diet
Description: A diet higher in carbohydrates and lower in fats and sugars
Study: NCT03343223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing.
Study: NCT04020848

Intervention type: OTHER
Intervention: Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.
Description: Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
Study: NCT02610374

Intervention type: OTHER
Group type: OTHER
Intervention: Agrarian Diet
Description: A diet higher in carbohydrates and lower in fats and sugars

Intervention type: OTHER
Group type: OTHER
Intervention: Agrarian Diet
Description: A diet higher in carbohydrates and lower in fats and sugars

Intervention type: OTHER
Group type: OTHER
Intervention: Western-type Diet
Description: A diet higher in fats and lower in carbohydrates
Study: NCT04170179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study: NCT00829413

Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue®
Description: SonoVue (2.4 mL)
Study: NCT01058421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive physical therapy
Description: four week course of daily intensive physical therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: four weeks of routine physical therapy
Study: NCT04414501

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Separation Anxiety
Description: Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Separation Anxiety
Description: Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
Study: NCT00358826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study: NCT04020848

Intervention type: OTHER
Intervention: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire
Description: Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
Study: NCT02709005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Monolaurin Vaginal Gel
Description: Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
Study: NCT00358826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: oral dosing, 1 time daily for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study: NCT02610374

Intervention type: OTHER
Group type: OTHER
Intervention: Western-type Diet
Description: A diet higher in fats and lower in carbohydrates
Study: NCT00358826

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 12 or 24 weeks
Study: NCT02903056

Intervention type: OTHER
Intervention: Rett Syndrome
Description: Diagnosis of Rett Syndrome

Intervention type: OTHER
Intervention: Rett Syndrome
Description: Diagnosis of Rett Syndrome
Study: NCT01110681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)
Study: NCT03651674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT treatment
Description: Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug treatment
Description: Patients only have antipsychotic drugs
Study: NCT04080024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN132D
Description: Novel manganese-based macromolecular MRI contrast agent
Study: NCT01560312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity® Catheter System™)
Description: 4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
Study: NCT02618603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study: NCT01422408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide Cream
Description: Given topically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive fluocinonide cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00960180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR1817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00566683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazemuls, pethidine
Description: 5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Alfentanil
Description: Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
Study: NCT03633942

Intervention type: DEVICE
Intervention: LMA Supreme
Description: Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
Study: NCT01496833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankura Branched/Fenestrated Stent Graft
Description: Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
Study: NCT01846793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: 2.5 mg NX-1207 in 10 mL saline vehicle
Study: NCT01896882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Study: NCT00343928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids
Description: Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
Study: NCT00703690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0767
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0767
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0767
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: fenofibrate
Description: fenofibrate 200 mg supplied as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: matching placebo will be supplied as tablets/capsules.
Study: NCT01417507

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Undergo neurocognitive assessment
Study: NCT02971358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Standard radical prostatectomy with extended lymph node dissection is performed.
Study: NCT03593824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cataract removal surgery for dense cataract
Description: Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cataract removal surgery for non-dense nuclear cataract
Description: Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
Study: NCT01417507

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: Undergo MRI

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02763514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 g PronovaPure 150:500 EE EU

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 g PronovaPure 500:200 EE EU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 g Placebo